Gossamer Bio, Inc. cash flow to debt ratio of -84.41% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Gossamer Bio, Inc.'s free cash flow has decreased 4.84K% from $-3.47M last year to $-171.34M, signaling decreasing performance

Gossamer Bio, Inc.'s debt to equity ratio is -1.26, signaling that the company spent its equity and risk bankruptcy.

Gossamer Bio, Inc.'s debt to equity ratio is -1.26, signaling that the company spent its equity and risk bankruptcy.

Gossamer Bio, Inc. has negative EBITDA, making leverage ratio unreliable

Gossamer Bio, Inc.'s interest coverage ratio is -16.26, which means that the company struggles to meet interest obligations, signaling financial risk.

Gossamer Bio, Inc.'s profit margin has decreased (559.10%) in the last year from -49.28% to -324.82%, signaling decreasing performance

Gossamer Bio, Inc.'s short-term assets of $167.64M exceed its short-term liabilities of $63.44M

Gossamer Bio, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Gossamer Bio, Inc.'s return on equity of 174.85%, is higher than 15.00%, indicating good performance

Gossamer Bio, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Gossamer Bio, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Gossamer Bio, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Gossamer Bio, Inc. has negative free cash flow, indicating cash burn

Gossamer Bio, Inc.'s yearly earnings has decreased 201.39% since last year from $-56.53M to $-170.37M, signaling decreasing performance

Gossamer Bio, Inc.'s yearly revenue has decreased -57.74% since last year from $114.70M to $48.47M, signaling decreasing performance

ROIC -243.62% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Gossamer Bio, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Gossamer Bio, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Gossamer Bio, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Gossamer Bio, Inc. has insufficient data to evaluate this check.

Gossamer Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Gossamer Bio, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Gossamer Bio, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Gossamer Bio, Inc. has insufficient data to evaluate this check.

Gossamer Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Gossamer Bio, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Gossamer Bio, Inc. has a price-to-sales ratio of 0.59x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue